2024 Press Releases 2024 2023 2022 2021 2020 Portfolio Companies New Leaf Portfolio Companies Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionApril 29, 2024 Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApril 29, 2024 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerApril 11, 2024 Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)April 10, 2024 Merck Completes Acquisition of Harpoon Therapeutics, IncMarch 11, 2024 CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International ConferenceMarch 7, 2024 New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood March 5, 2024 Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging SystemMarch 5, 2024 COGENT BIOSCIENCES ANNOUNCES POSITIVE PART 1B DATA FROM SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSISFebruary 22, 2024 Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseFebruary 20, 2024 New collaboration with Kyruus Health to advance care access and outcomes for patients at Nicklaus Children’s Health SystemFebruary 14, 2024 COGENT BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $225 MILLION PRIVATE PLACEMENTFebruary 14, 2024 TigerConnect is a 2024 Best in KLAS Award Winner for Clinical CommunicationsFebruary 7, 2024 Bluesight Demonstrates Industry-Leading Performance in Drug Diversion Detection; New Data Highlights 6.6X Advantage Over CompetitorsFebruary 7, 2024 Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerFebruary 6, 2024 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineJanuary 8, 2024